Literature DB >> 15906566

Association of the risk of development of hypothyroidism after iodine 131 treatment with the pretreatment pattern of sodium pertechnetate Tc 99m uptake in the thyroid gland in cats with hyperthyroidism: 165 cases (1990-2002).

Stephanie G Nykamp1, Nathen L Dykes, Mitzi K Zarfoss, Janet M Scarlett.   

Abstract

OBJECTIVE: To assess whether the risk of development of hypothyroidism after treatment with iodine 131 (131I) was associated with the pattern of sodium pertechnetate Tc 99m activity in the thyroid gland detected via scintigraphy before treatment in cats with hyperthyroidism.
DESIGN: Retrospective study. ANIMALS: 165 cats. PROCEDURE: Medical records of cats with hyperthyroidism that had been treated with 131I (from 1990 to 2002) and had undergone scintigraphy of the thyroid gland before treatment were reviewed; data regarding signalment, scintigraphic findings (classified as unilateral, bilateral-asymmetric, bilateral-symmetric, or multifocal patterns), serum total thyroxine (T4) concentrations before treatment and prior to hospital discharge, and 131I treatment were collected. A questionnaire was sent to each referring veterinarian to obtain additional data including whether the cats subsequently developed hypothyroidism (defined as serum total T4 concentration less than the lower reference limit > or = 3 months after treatment).
RESULTS: 50 of 165 (30.3%) 131I-treated cats developed hypothyroidism. Hypothyroidism developed in 39 of 109 cats with bilateral, 10 of 50 cats with unilateral, and 1 of 6 cats with multifocal scintigraphic patterns of their thyroid glands. Cats with a bilateral scintigraphic pattern were approximately 2 times as likely to develop hypothyroidism after 131I treatment than were cats with a unilateral scintigraphic pattern (hazard ratio, 2.1; 95% confidence interval, 1.04 to 4.2). CONCLUSIONS AND CLINICAL RELEVANCE: Cats with hyperthyroidism that have a bilateral scintigraphic pattern in the thyroid gland before 131I treatment appear to have a significantly higher risk of subsequently developing hypothyroidism, compared with cats with a unilateral scintigraphic pattern.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906566     DOI: 10.2460/javma.2005.226.1671

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Use of thyroid stimulating hormone (TSH) in cats.

Authors:  Jennifer Wakeling
Journal:  Can Vet J       Date:  2010-01       Impact factor: 1.008

2.  Assessment of serum symmetric dimethylarginine and creatinine concentrations in hyperthyroid cats before and after a fixed dose of orally administered radioiodine.

Authors:  Lucia Yu; Lauren Lacorcia; Sue Finch; Thurid Johnstone
Journal:  J Vet Intern Med       Date:  2020-06-07       Impact factor: 3.333

3.  Investigation of a novel variable dosing protocol for radioiodine treatment of feline hyperthyroidism.

Authors:  Wendy A Morré; David L Panciera; Gregory B Daniel; William E Monroe; Stephen Werre
Journal:  J Vet Intern Med       Date:  2018-10-17       Impact factor: 3.333

4.  Assessment of symmetric dimethylarginine as a biomarker of renal function in hyperthyroid cats treated with radioiodine.

Authors:  Eva Buresova; Emmelie Stock; Dominique Paepe; Lisa Stammeleer; Eva Vandermeulen; Pascale Smets; Luc Duchateau; Herve P Lefebvre; Sylvie Daminet
Journal:  J Vet Intern Med       Date:  2019-01-11       Impact factor: 3.333

5.  Changes in thyroid and renal function after bilateral thyroidectomy in cats.

Authors:  Heather L Covey; Yu-Mei Chang; Jonathan Elliott; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2019-02-13       Impact factor: 3.333

6.  Predicting outcomes in hyperthyroid cats treated with radioiodine.

Authors:  Mark E Peterson; Mark Rishniw
Journal:  J Vet Intern Med       Date:  2021-11-24       Impact factor: 3.333

7.  Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism.

Authors:  M E Peterson; F V Varela; M Rishniw; D J Polzin
Journal:  J Vet Intern Med       Date:  2018-01       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.